Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER-096 in Healthy Volunteers and Parkinson's Disease Patients
NCT06659562Phase 1Completed
- Sponsor
- Herantis Pharma
- Start
- Sep 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HER-096 in Parkinson's disease (PD) (3 arms), sponsored by Herantis Pharma. Primary endpoints: Treatment-Emergent Adverse Events, Physical Examination and 9 more. Started Sep 2024; status: completed.
02
Drugs
HER-096
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06659562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06659562.